34 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
without reimbursement or formal PMDA approval. Secondly, RepliCel has successfully completed the second of three consultations required to obtain … . This pathway leads to formal PMDA approval and reimbursement. Successful data from such a trial could lead to 'conditional approval' for market
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
) regulations. Successful safety and efficacy data from such a study can be sufficient to support market launch of a product albeit without reimbursement … to formal PMDA approval and reimbursement. Successful data from such a trial could lead to 'conditional approval' for market launch of RCT-01 in Japan
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
such a study can be sufficient to support market launch of a product albeit without reimbursement or formal PMDA approval. Secondly, RepliCel has … Agency, PMDA) to proceed with a clinical trial of RCT-01 under the PMD Act. This pathway leads to formal PMDA approval and reimbursement. Successful
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
and efficacy data from such a study can be sufficient to support market launch of a product albeit without reimbursement or formal PMDA approval. Secondly … and reimbursement. Successful data from such a trial could lead to ‘conditional approval’ for market launch of RCT-01 in Japan with reimbursement pending data from
20-F/A
jnrie45
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
4vejh
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
51tc zkzx
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.2
k2j xkgt4
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
cifh7nge
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
nwgta xle62v
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
6-K
EX-99.1
suhjd0
19 Mar 19
RepliCel Reignites its First-in-Japan Strategy
12:11pm
6-K
ye19s
24 Nov 10
Current report (foreign)
12:00am
6-K
il2n8 4den5beh
15 Oct 09
Current report (foreign)
12:00am